Demographics Significantly Influence Common Customer Behavior at Community Pharmacies
Drug Topics
MARCH 29, 2024
Researchers found various reasons for why individuals chose a specific pharmacy and how they purchase OTC medication.
Fri.Mar 29, 2024
220 
Why researchers think human milk could repair the gut microbiome and reduce infections
STAT
MARCH 29, 2024
For babies who are breastfed, their first source of sustenance is filled with proteins, sugars, hormones, vitamins, and minerals — just the right amount of nutrients for an infant. That milk could also lower the risk of asthma , diabetes, and allergies. And it could make low-birth-weight, preterm babies up to 10 times less likely to develop necrotizing enterocolitis , a common intestinal disorder.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Ozempic, Other GLP-1 Therapies Caused Major Increase in Medicare Spending
Drug Topics
MARCH 29, 2024
After semaglutide and tirzepatide were approved, and ozempic use continues to rise, Medicare spending is also increasing because of a high demand for GLP-1 therapies.
GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable
STAT
MARCH 29, 2024
Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13 times more expensive here than in comparable high-income countries. And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. The study, led by Melissa Barber, a Yale postdoctoral fellow, and conducted in collaboration with Doctors Without Borders, a nonprofit medical organization working
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Companies to Pay Medicare Rebates if Prices Rise Faster Than Inflation
Drug Topics
MARCH 29, 2024
Thanks to the Inflation Reduction Act, Medicare Part B coinsurance rates will lower if drug prices rise faster than the rate of inflation.
STAT+: Washington wants to avert another Change Healthcare-like fiasco. Here’s what could be coming
STAT
MARCH 29, 2024
Washington is cracking down on the technology running behind the scenes in health care following a debilitating cyberattack on a health care payments processing company — and it could have major implications for hospitals and the vendors selling crucial IT. In the weeks since a ransomware attack on Change Healthcare brought pharmacy and hospital payments across the country to a halt, policymakers and lobbyists have raced to cobble together strategies for averting future attacks, ranging f
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
'Things get built and forgotten about': The challenging work of maintaining AI tools in clinical settings
Fierce Healthcare
MARCH 29, 2024
With AI being all the buzz in healthcare today, many questions about the technology still remain. Do clinicians understand and trust AI tools? Are algorithms accurate and free from bias? | At the 2024 SXSW conference, a panel on the future of AI in healthcare moderated by AMA President Jesse Ehrenfeld, M.D., discussed what's still needed for safer, more integrated and more impactful systems.
Bristol Myers Squibb's versatile Zeposia doesn't make the grade in Crohn's disease trial
Fierce Pharma
MARCH 29, 2024
Bristol Myers Squibb’s Zeposia (ozanimod) has attracted attention as a treatment for an unusual duo of diseases—multiple sclerosis (MS) and ulcerative colitis (UC). | Bristol Myers Squibb’s Zeposia has attracted attention as a treatment for an odd pair of unrelated diseases—multiple sclerosis (MS) and ulcerative colitis (UC). But the approval roll for the sphingosine 1-phosphate (S1P) receptor modulator may be over.
Study Finds ALL Genetic Variant That Indicates Why Hispanic, Pediatric Patients Are Likely to Develop Disease
Pharmacy Times
MARCH 29, 2024
Pediatric patients with the variant were approximately 1.44 times more likely develop ALL compared with children who do not have the variant.
After Amgen's stumble, BMS touts KRAS confirmatory trial win for newly bought Krazati
Fierce Pharma
MARCH 29, 2024
Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout. | Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more
STAT
MARCH 29, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still being formulated, but we do hope to promenade with the official mascots, catch up on our reading, and maybe stare at the telly now and then. Of course, we are also planning another listening party, where the rotation will include this , this , this and this.
The unrecognized threat of PAD
Fierce Pharma
MARCH 29, 2024
This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged. | This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.
Industry Voices—Pregnant Medicaid beneficiaries need better access to prenatal vaccines. Simple state reforms can help
Fierce Healthcare
MARCH 29, 2024
As public health officials nationwide sound the alarm on a “tripledemic”—the emergence of the respiratory syncytial virus (RSV), the influenza virus and the COVID-19 virus simultaneously—pregnant w | Given that Medicaid and CHIP cover a significant portion of all pregnancies in America—especially for historically disadvantaged groups—policy actions could play a key role in supporting vaccine access and health equity.
What’s Congress going to do with WuXi?
STAT
MARCH 29, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at key Supreme Court decision, the latest biotech IPO, and intrigue over Chinese outsourcing.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Exposure to Residential Greenness During Pregnancy Associated With Increased Risk of Asthma
Pharmacy Times
MARCH 29, 2024
The effects were strongest during the spring season and in the third trimester of pregnancy.
Pharma Pulse 3/29/24: Social Media Users Turn to Twitter for Guidance on Birth Control, Wider Availability of Oral Contraceptives & more
Pharmaceutical Commerce
MARCH 29, 2024
The latest news for pharma industry insiders.
Researchers Identify Two Mutations Potentially Linked to Rare Blood Disorder
Pharmacy Times
MARCH 29, 2024
The mutations, C594Y and P735R, were found in the GNE gene and may influence sialylation, a process that is crucial for brain development.
Report claims WuXi shared US client IP with China
pharmaphorum
MARCH 29, 2024
Report claims US intelligence services advised the authors of the BIOSECURE Act that WuXi AppTec shared confidential data on US clients with the Chinese government
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Rising Tide of Biopharma Manufacturing Costs
Pharmaceutical Commerce
MARCH 29, 2024
In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses the specific factors contributing to rising manufacturing costs.
Disappointment for BMS as Zeposia fails Crohn’s study
pharmaphorum
MARCH 29, 2024
Bristol-Myers Squibb's Zeposia has failed to outperform placebo in its first phase 3 test in Crohn's disease
STAT+: Up and down the ladder: The latest comings and goings
STAT
MARCH 29, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
'Unprecedented' demand for Eli Lilly's Zepbound sparks US supply constraints
Fierce Pharma
MARCH 29, 2024
Once again, a medicine in the popular GLP-1 class of diabetes and weight loss therapies is facing supply hurdles. | While the drug is not listed on the FDA's shortage list, some pharmacies are facing supply issues. Amazon Pharmacy, for instance, notes that several dosage strengths are "unavailable.
Novel LAI antipsychotic approved in EU
European Pharmaceutical Review
MARCH 29, 2024
The first once-every-two-months long-acting injectable (LAI) antipsychotic approved by the European Commission (EC) is authorised as maintenance treatment for adults with schizophrenia in the EU. The European Commission’s decision for this formulation of Abilify Maintena ® 960mg (aripiprazole) is applicable to all EU Member States, in addition to Iceland, Norway and Liechtenstein.
Direct Oral Anticoagulant Use for Left Ventricular Thrombus Treatment
Pharmacy Times
MARCH 29, 2024
An overview of the use of direct oral anticoagulants as an alternative to warfarin in the treatment of left ventricular thrombus.
Teva, following Hikma complaint, alleges Amarin 'locked up' Vascepa ingredient to block generics
Fierce Pharma
MARCH 29, 2024
A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart po | A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart potential generic competition, Teva Pharmaceuticals has levied a similar challenge.
FDA Grants ODD to AP303 for Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease
Pharmacy Times
MARCH 29, 2024
The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.
To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach
PharmaVoice
MARCH 29, 2024
Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.
Pharmacy Focus: OTC Contraception and Reproductive Health
Pharmacy Times
MARCH 29, 2024
Christin Hackel discusses the current state of OTC contraception options, the differences between OTC and prescription methods, and how pharmacists can promote education and awareness.
Brightside Health secures $33M to propel expansion into Medicare, Medicaid populations
Fierce Healthcare
MARCH 29, 2024
Virtual mental health company Brightside Health picked up $33 million in fresh funding to help propel its expansion into Medicare and Medicaid populations. | Virtual mental health company Brightside Health picked up $33 million in fresh funding to help propel its expansion into Medicare and Medicaid populations.
The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment
Compounding Pharmacy of America
MARCH 29, 2024
An exploration of how proper diet, exercise, and a regiment of supplements combined with GLP-1 therapies can prevent and treat type 2 diabetes. The post The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment appeared first on The Compounding Pharmacy of America.
GAO Report on Clinical Research Inspections Encourages FDA to Care for its Clinical Inspection Program
The FDA Law Blog
MARCH 29, 2024
By John W.M. Claud & Kalie E. Richardson — While Covid is in the rear view for most of us, FDA has had a tough time shaking off the effects of the pandemic on its inspection output. Inspections went down—way down—during the pandemic. In March 2020 , FDA temporarily postponed all foreign and domestic and routine surveillance facility inspections.
Payer Roundup—UnitedHealth clean energy plan will supply most of U.S. electrical load; How Blue Shield of California is tackling Oakland crime
Fierce Healthcare
MARCH 29, 2024
Payer Roundup—UnitedHealth clean energy plan will supply most of U.S.
In Search of the ‘Bad Guy’
Pharmaceutical Commerce
MARCH 29, 2024
Fighting for patient affordability doesn’t necessarily require a scapegoat.
Let's personalize your content